MetaCap

Lineage Cell Therapeutics Statistics

NYSE: LCTXHealth CareBiotechnology: Biological Products (No Diagnostic Substances)USD

0.7719-0.0481 (-5.87%)

At close: Nov 20, 4:00 PM ET · Delayed 15 min

Lineage Cell Therapeutics by the numbers

Lineage Cell Therapeutics has a market capitalization of $195.3 million based on 252.95M shares outstanding. With trailing EPS of $-0.09, Lineage Cell Therapeutics is unprofitable on a 12-month basis, so earnings-based valuation ratios do not apply. The stock trades 20.8% below its 50-day average and 39.5% below its 200-day average.

Average daily trading volume is 1.64M shares, or about $1.3 million in dollar volume.

Summary generated from market data by MetaCap's automated system. Methodology

LCTX valuation vs. peer median

LCTX compared with the median of 8 peer companies
MetricLCTXPeer medianDifference
Market cap$195.26M$194.40M+0%
Avg. volume1.64M775.98K+112%

Peer median across 8 companies: CABA, ARTV, IKT, IPSC, CGEN, ALLO, SCTX, PALI.

Valuation

Market cap
$195.26M
Price / sales (latest FY)
13.41
EPS (TTM)
$-0.09

Price and trading

Previous close
0.82
Open
0.81
Day range
0.77 – 0.8383
52-week range
0.77 – 1.99
52-week change
-55.64%
Beta
—
Volume
2.04M

Dividends and events

Annual dividend
None
Next earnings date
Nov 12, 2026

Additional statistics

Market Cap
195.26M
Forward Pe
-7.02
Eps
-0.09
Dividend Yield
0.00%
Dividend Rate
0.00
Week52 High
1.99
Week52 Low
0.77
Avg Volume
1.64M
Shares Outstanding
252.95M
Ma50
0.97
Ma200
1.28
Earnings Date
Nov 12, 2026
Pct From52w High
-61.21%
Pct From52w Low
0.25%

Related